COMPANY ANNOUNCEMENT
- Large Brain+ shareholders have committed to exercise warrants for
DKK 1.6 million or 28% of the total outstanding - Members of board and management have doubled their announced commitments to
DKK 0.4 million or 7% of the total outstanding, providingDKK 0.2 million in guarantees, - The exercise price for the warrants of series TO 2 has been set at
DKK 0.20 and the exercise period runs from 2 -16 October 2023
Brain+ A/S ("Brain+") announces that six of the company's largest shareholders, including seasoned life science investors, have so far committed to exercise warrants of series TO 2, corresponding to 28% of the total outstanding and
Six of the company's largest shareholders, which include seasoned life-science investors from both
The combined continued commitment from these investors secures the company approximately
Furthermore, members of the board and management have today jointly undertaken, in addition to their previously announced commitment to exercise all their warrants of series TO 2 (see Company Announcement from
Summary of commitments provided so far by shareholders and members of the company's board and management:
Position in Brain+ | Committed exercise (DKK) | Guarantee commitment (DKK) | Total committed amount (DKK) | |
Private investor | 572,120 | 572,120 | ||
Private investor | 400,000 | 400,000 | ||
Private investor | 300,000 | 300,000 | ||
Members of Danish family (anonymous) | Private investors | 333,075 | 333,075 | |
CEO, Co-founder | 12,000* | 12,000* | ||
Anders Härfstrand | Chairman of the Board | 96,000* | 96,000* | |
CFO | 52,618* | 52,618* | ||
Member of the board | 48,000* | 48,000* | ||
Kim, Anders, Hanne and Johan | Members of board and management | 196,982 | 196,982 | |
Total (DKK) | 1,813,813 | 196,982 | 2,010,795 |
*Communicated in a company announcement on
Complete terms and conditions for the warrants of series TO 2 can be found in the prospectus approved by the
The approved prospectus as well as additional informative documents, including a Brain+ investor teaser and a FAQ summary related to the exercise of warrants of series TO 2, are available on the Company's webpage under Exercise of TO2 warrants - Brain+ Better brain better life (brain-plus.com). The prospectus is also available on the Danish Financial Supervisory Authority's website (https://oam.finanstilsynet.dk).
Summarized terms for the warrants of series TO2:
Exercise period: |
2 - |
Exercise price: | |
Last day of trading in warrants of series TO 2: | |
Issue volume: |
28,542,348 warrants of series TO 2 which entitle to a maximum subscription of 28.542,348 new shares in the Company. If all warrants are exercised, Brain+ will receive proceeds of approximately |
Dilution: |
Upon full exercise of warrants of series TO 2, the number of shares of nominal value |
Advisors
In connection with the unit rights issue including the issue and exercise of warrants of series TO 2,
For more information about the warrant exercise, please contact:
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Gemstone
Phone: +45 33 22 07 00
E-mail: sh@gemstonecapital.com
www.gemstonecapital.com
For more information about Brain+, please contact:
Phone: +45 31 39 33 17
E-mail: kim@brain-plus.com
www.brain-plus.com
Certified Adviser
Phone: +43 1 740 408 045
E-mail: info@keswickglobal.com
https://news.cision.com/brain--a-s/r/brain--announces-commitments-from-its-largest-shareholders-in-the-ongoing-exercise-of-warrants-of-se,c3850707
https://mb.cision.com/Public/20893/3850707/a8045977da163a82.pdf
https://news.cision.com/brain--a-s/i/1-b-en-rgb,c3223834
(c) 2023 Cision. All rights reserved., source